8:00 am Coffee & Networking

Strategy – Selection – Characterization

8:30 am Providing Translational Support for TSR Programs

  • Geeta Sharma Scientific Fellow, Translational Research, Tesaro

Synopsis

• Presentation details to be confirmed

8:55 am Models to Understand the Mechanisms of Action of Cancer Biologic Therapies

  • Dan Powell Director, Clinical Tumor Tissue Facility & Associate Professor , University of Pennsylvania

Synopsis

  • Showcasing the testing of new antibody combinations that activate tumorreactive T cells and simultaneously blocking checkpoint molecules that dampen host antitumor immunity
  • Revealing the development of new model systems to screen immunomodulatory agents in vitro and in vivo

9:20 am Immunoprofiling of Murine Tumor Models to Improve the Translational Prediction of Immune-Based Therapeutics

  • Hervé Luche Scientific Director Immunophenotyping Unit , Inserm Centre D’Immunoph- ENomique
  • Ana Zarubica COO , Inserm Centre D’Immunoph- ENomique

Synopsis

  • Demonstrating tumor cell line editing by CrispR/Cas9 in B6 and BalbC Syngeneics, GEMs
  • Showcasing a standardized experimental approach to manage cohorts of up to 48 animals for multi-variate multi-group studies
  • Sharing insights on the massive parallel Immunoprofiling of multiple tissues by flow/spectral/mass cytometry
  • Revealing advanced data analysis methodologies to identify cell subsets correlates to a treatment candidate

9:45 am Q&A Panel – Strategy – Selection – Characterization

  • Geeta Sharma Scientific Fellow, Translational Research, Tesaro
  • Dan Powell Director, Clinical Tumor Tissue Facility & Associate Professor , University of Pennsylvania
  • Hervé Luche Scientific Director Immunophenotyping Unit , Inserm Centre D’Immunoph- ENomique
  • Ana Zarubica COO , Inserm Centre D’Immunoph- ENomique

10:15 am Morning Refreshments

Precision Gene Editing for Disease Modelling and Target Validation

11.05 Applications of Next Generation Genetic Engineering Approaches

  • Overview of GEM models and progress towards further humanising and recapitulating the immune response at earlier immune privileged states
  • Moving towards organoids, The advantages of developing CRISPR-edited tumoroids in vitro to study specific tumor-driven pathways
  • Exploring how to develop flexible strategies with iPSC derived organoids cultures to maximize predictability and translatability of early discoveries

Andrew Rhim, Associate Director - Translational Research & Assistant Professor – Gastroenterology, MD Anderson Cancer Center


11.30 Transgenic Manipulation of Tumor Organoids for “Personalized” Modeling of Diverse Tumor Subtypes

  • Strategies for combining single-copy somatic transgenesis with CRISPR genome editing to generate patient-derived mutation signatures in in vivo mouse and 3D human organoid models to accurately model clinical tumor subtypes in a “personalized” manner
  • Methodologies for interrogating human tumor heterogeneity over space and time as well as for credentialing of models with single-cell RNA sequencing
  • Examples of preclinical studies investigating strategies to impede tumor growth and development by immunotherapy, metabolic targeting, and therapeutic mimicry

Joshua Breunig, Assistant Professor, Cedars-Sinai Medical Center


11.55 Using 3D Tumor Models to Investigate the Role of Immune Cells on the CSC Niche

  • Discussing the role of Cancer Stem Cell and Immune cell interactions in drug response and resistance
  • Highlighting novel preclinical models in the development of therapies targeting cancer stem cells
  • Exploring the contribution of the CSC niche to tumor initiation and progression and examine the prospects of targeting the niche for cancer therapy

Esmaiel Jabbari, Professor, University of South Carolina


12.20 Q&A Panel - Precision Gene Editing For Disease Modelling & Target Validation

Andrew Rhim, Associate Director - Translational Research & Assistant Professor – Gastroenterology, MD Anderson Cancer Center

Joshua Breunig, Assistant Professor, Cedars-Sinai Medical Center

Esmaiel Jabbari, Professor, University of South Carolina

Models and Strategies to Bridge the Combination Gap

12:40 pm Lunch

1:40 pm Round Table Discussions

Synopsis

Picking up on the day’s presentations, this session provides you with the opportunity to drive your own learning, crowdsource ideas and discover multiple perspectives for selecting, characterising and building the confidence in tumor model application areas. Over the hour, each breakout will discuss the below questions. Feedback from each group will be collated and presented as part of the moderator panel.

2:30 pm Moderator Feedback Panel

2:40 pm Afternoon Refreshments

Models Aiding Dose Translation and Understanding Drug Response

3:10 pm Challenges & Opportunities in Understanding Drug Exposure at The Site Of Action Within Pre-Clinical Tumor Models And The Potential Implications Of Transporter Mediated Efflux

Synopsis

  • Exploring the challenges in evaluating free drug exposure in the tumor models, the methods used to measure and make an estimate relative concentrations observed in plasma
  • Examples of differences in exposure in tumors between compounds will be highlighted along with the potential implications when interpreting efficacy data

3:35 pm NCI’s Patient Derived Models Repository Quality Control and Preclinical Efforts

  • Yvonne Evrard Operations Manager , National Institute of Health Sciences

Synopsis

  • Highlighting the progress towards development of >1000 PDX models along with matched in vitro and organoid models wherever possible
  • Showcasing the comprehensive characterization of early-passage models: RNAseq, histology, growth curves, and preclinical drug responses
  • Exploring the assessment of tumor heterogeneity on target qualification or clinical response, whether PDXs more faithfully represent the human tumor for pharmacodynamic assay and predictive marker development and if adequately powered preclinical PDX-trials lead to better evaluation of therapies for future clinical use

4:00 pm Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response

  • Rhys Jones Senior Director DMPK , Pfizer
  • Yvonne Evrard Operations Manager , National Institute of Health Sciences

4:20 pm Close of Conference